研究業績

2024

1.	Fujii H, Iwaki M, Kamada Y. Correspondence on Letter regarding “Prognosis of biopsy-confirmed MASLD: A sub-analysis of the CLIONE study” Clin Mol Hepatol. 2024;30(2):281-283. doi.org/. doi: 10.3350/cmh.2024.0214.

2.	Kumada T, Toyoda H, Ogawa S, Gotoh T, Suzuki Y, Sugimoto K, Yoshida Y, Kuroda H, Kamada Y, Sumida Y, Ito T, Akita T, Tanaka J. Severe hepatic steatosis promotes increased liver stiffness in the early stages of metabolic dysfunction-associated steatotic liver disease. Liver Int. 2024 Apr 1. doi.org/. doi: 10.1111/liv.15920. Online ahead of print.PMID: 38558221.

3	Hirooka M, Ogawa S, Koizumi Y, Yoshida Y, Goto T, Yasuda S, Yamahira M, Tamai T, Kuromatsu R, Matsuzaki T, Suehiro T, Kamada Y, Sumida Y, Hiasa Y, Toyoda H, Kumada T. iATT liver fat quantification for steatosis grading by referring to MRI proton density fat fraction: a multicenter study. J Gastroenterol. 2024 Mar 30. doi.org/. doi: 10.1007/s00535-024-02096-w. Online ahead of print.PMID: 38553657.

4.	Kumada T, Toyoda H, Ogawa S, Gotoh T, Yoshida Y, Yamahira M, Hirooka M, Koizumi Y, Hiasa Y, Tamai T, Kuromatsu R, Matsuzaki T, Suehiro T, Kamada Y, Sumida Y, Tanaka J, Shimizu M. Diagnostic performance of shear wave measurement in the detection of hepatic fibrosis: A multicenter prospective study. Hepatol Res. 2024, Feb 13. doi.org/. doi: 10.1111/hepr.14026. Online ahead of print.PMID: 38349813.

5.	Iwaki M, Fujii H, Hayashi H, Toyoda H, Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Tsutsumi T, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Prognosis of biopsy-confirmed MASLD: a sub-analysis of the CLIONE study. Clin Mol Hepatol. 2024, Jan 24. doi.org/. doi: 10.3350/cmh.2023.0515. Online ahead of print.PMID: 38263684.

Iwaki M, Fujii H, Hayashi H, Toyoda H, Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Tsutsumi T, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Prognosis of biopsy-confirmed MASLD: a sub-analysis of the CLIONE study. Clin Mol Hepatol. 2024, Jan 24. doi.org/. doi: 10.3350/cmh.2023.0515. Online ahead of print.PMID: 38263684.

6.	Manabe Y, Hizume K, Takakura Y, Takamatsu S, Miyoshi E, Kamada Y, Hurtado-Guerrero R, Fukase K. Systematic Strategy for the Development of Glycosyltransferase Inhibitors: Diversity-Oriented Synthesis of FUT8 Inhibitors. Synlett. 2024. 35, A-F doi.org/. doi: 10.1055/a-2221-9096. Online ahead of print.

2023

1.	Arai T, Takahashi H, Seko Y, Toyoda H, Hayashi H, Yamaguchi K, Iwaki M, Yoneda M, Shima T, Fujii H, Morishita A, Kawata K, Tomita K, Kawanaka M, Yoshida Y, Ikegami T, Notsumata K, Oeda S, Atsukawa M, Kamada Y, Sumida Y, Fukushima H, Miyoshi E, Aishima S, Okanoue T, Itoh Y, Nakajima A; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD) Accuracy of the enhanced liver fibrosis test in patients with type 2 diabetes mellitus and its clinical implications. Clin Gastroenterol Hepatol. 2023, Dec 2:S1542-3565(23)00961-8. doi.org/. doi: 10.1016/j.cgh.2023.11.022. Online ahead of print.

Arai T, Takahashi H, Seko Y, Toyoda H, Hayashi H, Yamaguchi K, Iwaki M, Yoneda M, Shima T, Fujii H, Morishita A, Kawata K, Tomita K, Kawanaka M, Yoshida Y, Ikegami T, Notsumata K, Oeda S, Atsukawa M, Kamada Y, Sumida Y, Fukushima H, Miyoshi E, Aishima S, Okanoue T, Itoh Y, Nakajima A; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD) Accuracy of the enhanced liver fibrosis test in patients with type 2 diabetes mellitus and its clinical implications. Clin Gastroenterol Hepatol. 2023, Dec 2:S1542-3565(23)00961-8. doi.org/. doi: 10.1016/j.cgh.2023.11.022. Online ahead of print.

2.	Ito T, Morooka H, Takahashi H, Fujii H, Iwaki M, Hayashi H, Toyoda H, Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Tsutsumi T, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Ishigami M, Kamada Y, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T; (JSG-NAFLD) Identification of clinical phenotypes associated with poor prognosis in patients with nonalcoholic fatty liver disease via unsupervised machine learning. J Gastroenterol Hepatol 2023 Oct;38(10):1832-1839. doi.org/. doi: 10.1111/jgh.16326. Online ahead of print.PMID: 37596843.

Ito T, Morooka H, Takahashi H, Fujii H, Iwaki M, Hayashi H, Toyoda H, Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Tsutsumi T, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Ishigami M, Kamada Y, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T; (JSG-NAFLD) Identification of clinical phenotypes associated with poor prognosis in patients with nonalcoholic fatty liver disease via unsupervised machine learning. J Gastroenterol Hepatol 2023 Oct;38(10):1832-1839. doi.org/. doi: 10.1111/jgh.16326. Online ahead of print.PMID: 37596843.

3.	Toyoda H, Fujii H, Iwaki M, Hayashi H, Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Yamamura S, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Kawada N, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T. (JSG-NAFLD) Validation of noninvasive markers for HCC risk stratification in 1,389 patients with biopsy-proven NAFLD. Gastro Hep Advances 2023, 1093-1102 doi.org/. doi: 10.1016/j.gastha.2023.07.018.

Toyoda H, Fujii H, Iwaki M, Hayashi H, Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Yamamura S, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Kawada N, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T. (JSG-NAFLD) Validation of noninvasive markers for HCC risk stratification in 1,389 patients with biopsy-proven NAFLD. Gastro Hep Advances 2023, 1093-1102 doi.org/. doi: 10.1016/j.gastha.2023.07.018.

4.	Fujii H, Suzuki Y, Sawada K, Tatsuta M, Maeshiro T, Tobita H, Tsutsumi T, Akahane T, Hasebe C, Kawanaka M, Kessoku T, Eguchi Y, Syokita H, Nakajima A, Kamada T, Yoshiji H, Kawaguchi T, Sakugawa H, Morishita A, Masaki T, Ohmura T, Watanabe T, Kawada N, Yoda Y, Enomoto N, Ono M, Fuyama K, Okada K, Nishimoto N, Ito YM, Kamada Y, Takahashi H, Sumida Y. (JSG-NAFLD) Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2014 to 2018 in Japan: A large-scale multicenter retrospective study. Hepatol Res 2023 Nov;53(11):1059-1072. doi.org/. doi: 10.1111/hepr.13947. Online ahead of print.PMID: 37537735.

Fujii H, Suzuki Y, Sawada K, Tatsuta M, Maeshiro T, Tobita H, Tsutsumi T, Akahane T, Hasebe C, Kawanaka M, Kessoku T, Eguchi Y, Syokita H, Nakajima A, Kamada T, Yoshiji H, Kawaguchi T, Sakugawa H, Morishita A, Masaki T, Ohmura T, Watanabe T, Kawada N, Yoda Y, Enomoto N, Ono M, Fuyama K, Okada K, Nishimoto N, Ito YM, Kamada Y, Takahashi H, Sumida Y. (JSG-NAFLD) Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2014 to 2018 in Japan: A large-scale multicenter retrospective study. Hepatol Res 2023 Nov;53(11):1059-1072. doi.org/. doi: 10.1111/hepr.13947. Online ahead of print.PMID: 37537735.

5.	Takahashi H, Kawanaka M, Fujii H, Iwaki M, Hayashi H, Toyoda H, Oeda S, Hyogo H, Morishita A, Munekage K, Kawata K, Tsutsumi T, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Kamada Y, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T. Association of Serum Albumin Levels and Long-Term Prognosis in Patients with Biopsy-Confirmed Nonalcoholic Fatty Liver Disease. Nutrients 2023, 15(9) doi.org/. doi: 10.3390/nu15092014.

Takahashi H, Kawanaka M, Fujii H, Iwaki M, Hayashi H, Toyoda H, Oeda S, Hyogo H, Morishita A, Munekage K, Kawata K, Tsutsumi T, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Kamada Y, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T. Association of Serum Albumin Levels and Long-Term Prognosis in Patients with Biopsy-Confirmed Nonalcoholic Fatty Liver Disease. Nutrients 2023, 15(9) doi.org/. doi: 10.3390/nu15092014.

6.	Fujii H, Takahashi H, Kamada Y, Sumida Y, Nakajima A. Reconsidering low HDL-cholesterol levels as a predictive factor for the development of hepatocellular carcinoma. JHEP Reports 2023doi.org/. doi: 10.1016/j.jhepr.2023.100752.

7.	Miura K, Hayashi H, Kamada Y*, Fujii H, Takahashi H, Oeda S, Iwaki M, Kawaguchi T, Tomita E, Yoneda M, Tokushige A, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T. Agile 3+ and Agile 4, non-invasive tests for liver fibrosis, are excellent formulae to predict liver-related events in nonalcoholic fatty liver disease. Hepatol Res 2023 Oct;53(10):978-988. doi.org/. doi: 10.1111/hepr.13938. Online ahead of print. PMID: 37353881.

Miura K, Hayashi H, Kamada Y*, Fujii H, Takahashi H, Oeda S, Iwaki M, Kawaguchi T, Tomita E, Yoneda M, Tokushige A, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T. Agile 3+ and Agile 4, non-invasive tests for liver fibrosis, are excellent formulae to predict liver-related events in nonalcoholic fatty liver disease. Hepatol Res 2023 Oct;53(10):978-988. doi.org/. doi: 10.1111/hepr.13938. Online ahead of print. PMID: 37353881.

8.	Morishita K, Kondo J, Sakon D, Hayashibara A, Tamura I, Shimizu K, Takamatsu S, Murata K, Kamada Y, Miyoshi E. Prohaptoglobin is a possible prognostic biomarker for colorectal cancer. Biochem Biophys Res Commun 2023 Jun 9;672:72-80. doi.org/. doi: 10.1016/j.bbrc.2023.06.017.Online ahead of print. PMID: 37343317.

9.	Hayashi H, Kamada Y*, Fujii H, Takahashi H, Oeda S, Iwaki M, Kawaguchi T, Tomita E, Yoneda M, Tokushige A, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Prediction of Liver-Related Events With a Combination of Liver Stiffness Measurements and Controlled Attenuation Parameters in Japanese Patients With Biopsy-Proven Non-alcoholic Fatty Liver Disease. Ultrasound Med Biol 2023 Apr 27:S0301-5629(23)00109-6. doi.org/. doi: 10.1016/j.ultrasmedbio.2023.03.023.Online ahead of print. PMID: 37120329.

Hayashi H, Kamada Y*, Fujii H, Takahashi H, Oeda S, Iwaki M, Kawaguchi T, Tomita E, Yoneda M, Tokushige A, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Prediction of Liver-Related Events With a Combination of Liver Stiffness Measurements and Controlled Attenuation Parameters in Japanese Patients With Biopsy-Proven Non-alcoholic Fatty Liver Disease. Ultrasound Med Biol 2023 Apr 27:S0301-5629(23)00109-6. doi.org/. doi: 10.1016/j.ultrasmedbio.2023.03.023.Online ahead of print. PMID: 37120329.

10.	Muranaka M, Takamatsu S, Ouchida T, Kanazawa Y, Kondo J, Nakagawa T, Egashira Y, Fukagawa K, Gu J, Okamoto T, Kamada Y, Miyoshi E. Vesicular Integral-Membrane Protein 36 Is Involved in the Selective Secretion of Fucosylated Proteins into Bile Duct-like Structures in HepG2 Cells. Int J Mol Sci 2023, ;24(8):7037. doi.org/. doi: 10.3390/ijms24087037.PMID: 37108200

11.	Ouchida T, Maeda H, Akamatsu Y, Maeda M, Takamatsu S, Kondo J, Misaki R, Kamada Y, Ueda M, Ueda K, Miyoshi E. The specific core fucose-binding lectin Pholiota squarrosa lectin (PhoSL) inhibits hepatitis B virus infection in vitro. Sci Rep. 2023 Apr 15;13(1):6175. doi.org/. doi: 10.1038/s41598-023-28572-6.PMID: 37061516

12.	Oeda S, Seko Y, Hayashi H, Arai T, Iwaki M, Yoneda M, Shima T, Notsumata K, Ikegami T, Fujii H, Toyoda H, Miura K, Morishita A, Kawata K, Tomita K, Kawanaka M, Isoda H, Yamaguchi K, Fukushima H, Kamada Y, Sumida Y, Aishima S, Itoh Y, Okanoue T, Nakajima A, Takahashi H. Validation of the utility of Agile scores to identify advanced fibrosis and cirrhosis in Japanese patients with nonalcoholic fatty liver disease. Hepatol Res 2023 doi.org/. doi: 10.1111/hepr.13890. Online ahead of print.PMID: 36807720

12.

Oeda S, Seko Y, Hayashi H, Arai T, Iwaki M, Yoneda M, Shima T, Notsumata K, Ikegami T, Fujii H, Toyoda H, Miura K, Morishita A, Kawata K, Tomita K, Kawanaka M, Isoda H, Yamaguchi K, Fukushima H, Kamada Y, Sumida Y, Aishima S, Itoh Y, Okanoue T, Nakajima A, Takahashi H. Validation of the utility of Agile scores to identify advanced fibrosis and cirrhosis in Japanese patients with nonalcoholic fatty liver disease. Hepatol Res 2023 doi.org/. doi: 10.1111/hepr.13890. Online ahead of print.PMID: 36807720

13.	Ishiba H, Sumida Y, Kamada Y, Fujii H, Iwaki M, Hayashi H, Toyoda H, Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Tsutsumi T, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Takahashi H, Ueda S, Aishima S, Nakajima A, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Noninvasive tests predict liver-related events and mortality in patients with non-alcoholic fatty liver disease: sub-analysis of the CLIONE-Asia study. J Gastroenterol Hepatol. 2023 doi.org/doi: 10.1111/jgh.16144. Online ahead of print.PMID: 36797989

13.

Ishiba H, Sumida Y, Kamada Y, Fujii H, Iwaki M, Hayashi H, Toyoda H, Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Tsutsumi T, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Takahashi H, Ueda S, Aishima S, Nakajima A, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Noninvasive tests predict liver-related events and mortality in patients with non-alcoholic fatty liver disease: sub-analysis of the CLIONE-Asia study. J Gastroenterol Hepatol. 2023 doi.org/doi: 10.1111/jgh.16144. Online ahead of print.PMID: 36797989

14.	Asuka T, Kamada Y, Morishita K, Fukuoka T, Takamatsu S, Kondo J, Watanabe M, Sakai N, Hayakawa K, Miyoshi E; Osaka Twin Research Group. Twin research shows glycan changes are more susceptible to environmental factors than their carrier glycoproteins. Glycoconj J. 2023 doi.org/10.1007/s10719-023-10099-7. Online ahead of print.PMID: 36787035

15.	Fujii H, Fujii M, Iwaki M, Hayashi H, Toyoda H, Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Tsutsumi T, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Kawada N, Tokushige A, Kamada Y*, Takahashi H, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T. A multicenter, retrospective, cohort study shows platelet counts predict HCC development in patients with NAFLD. Hepatol Res. 2023 Jan 27. doi: 10.1007/s10719-023-10099-7. Online ahead of print.PMID: 36787035

15.

Fujii H, Fujii M, Iwaki M, Hayashi H, Toyoda H, Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Tsutsumi T, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Kawada N, Tokushige A, Kamada Y*, Takahashi H, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T. A multicenter, retrospective, cohort study shows platelet counts predict HCC development in patients with NAFLD. Hepatol Res. 2023 Jan 27. doi: 10.1007/s10719-023-10099-7. Online ahead of print.PMID: 36787035

16.	Kamada Y, Nakamura T, Isobe S, Hosono K, Suama Y, Ohtakaki Y, Nauchi A, Yasuda N, Mitsuta S, Miura K, Yamamoto T, Hosono T, Yoshida A, Kawanishi I, Fukushima H, Kinoshita M, Umeda A, Kinoshita Y, Fukami K, Miyawaki T, Fujii H, Yoshida Y, Kawanaka M, Hyogo H, Morishita A, Hayashi H, Tobita H, Tomita K, Ikegami T, Takahashi H, Yoneda M, Jun DW, Sumida Y, Okanoue T, Nakajima A; JANIT Forum. SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: An expert review by the JANIT Forum. J Gastroenterol. 2023 Feb;58(2):79-97. doi.org/10.1007/s00535-022-01932-1.PMID: 36469127 Free PMC article.

16.

Kamada Y, Nakamura T, Isobe S, Hosono K, Suama Y, Ohtakaki Y, Nauchi A, Yasuda N, Mitsuta S, Miura K, Yamamoto T, Hosono T, Yoshida A, Kawanishi I, Fukushima H, Kinoshita M, Umeda A, Kinoshita Y, Fukami K, Miyawaki T, Fujii H, Yoshida Y, Kawanaka M, Hyogo H, Morishita A, Hayashi H, Tobita H, Tomita K, Ikegami T, Takahashi H, Yoneda M, Jun DW, Sumida Y, Okanoue T, Nakajima A; JANIT Forum. SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: An expert review by the JANIT Forum. J Gastroenterol. 2023 Feb;58(2):79-97. doi.org/10.1007/s00535-022-01932-1.PMID: 36469127 Free PMC article.

17.	Fujii H, Iwaki M, Hayashi H, Toyoda H, Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Yamamura S, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Kawada N, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-Based Cohort Study. Clin Gastroenterol Hepatol. 2023 Feb;21(2):370-379. doi: 10.1016/j.cgh.2022.01.002

17.

Fujii H, Iwaki M, Hayashi H, Toyoda H, Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Yamamura S, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Kawada N, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-Based Cohort Study. Clin Gastroenterol Hepatol. 2023 Feb;21(2):370-379. doi: 10.1016/j.cgh.2022.01.002

2022

1.	Kamada Y, Munekage K, Nakahara T, Fujii H, Sawai Y, Doi Y, Hyogo H, Sumida Y, Imai Y, Miyoshi E, Ono M.: Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). The FIB-4 Index Predicts the Development of Liver-Related Events, Extrahepatic Cancers, and Coronary Vascular Disease in Patients with NAFLD. Nutrients 2022 15(1), 66. doi.org/10.3390/nu15010066

2.	Saga A, Koseki M, Kanno K, Chang J, Higo T, Okuzaki D, Okada T, Inui H, Asaji M, Tanaka K, Omatsu T, Nishihara S, Zhu Y, Ito K, Hattori H, Ichi I, Kamada Y, Ono M, Saibara T, Ohama T, Hikoso S, Nishida M, Yamashita S, Sakata Y. A Dietary Oxysterol, 7-Ketocholesterol, Exacerbates Imiquimod-Induced Psoriasis-like Dermatitis inSteatohepatitic Mice.Int J Mol Sci. 2022 Dec 13;23(24):15855. doi.org/10.3390/ijms232415855.PMID: 36555497

Saga A, Koseki M, Kanno K, Chang J, Higo T, Okuzaki D, Okada T, Inui H, Asaji M, Tanaka K, Omatsu T, Nishihara S, Zhu Y, Ito K, Hattori H, Ichi I, Kamada Y, Ono M, Saibara T, Ohama T, Hikoso S, Nishida M, Yamashita S, Sakata Y. A Dietary Oxysterol, 7-Ketocholesterol, Exacerbates Imiquimod-Induced Psoriasis-like Dermatitis inSteatohepatitic Mice.Int J Mol Sci. 2022 Dec 13;23(24):15855. doi.org/10.3390/ijms232415855.PMID: 36555497

3.	Shirai K, Hikita H, Sakamori R, Doi A, Tahata Y, Sakane S, Kamada Y, Murai K, Nishio A, Yamada R, Kodama T, Nozaki Y, Kakita N, Ishida H, Nakanishi F, Morishita N, Imanaka K, Sakakibara M, Tatsumi T, Miyoshi E, Takehara T. Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosis. PLoS One. 2022 Dec 21;17(12):e0279416. doi.org/10.1371/journal.pone.0279416. PMID: 36542633

Shirai K, Hikita H, Sakamori R, Doi A, Tahata Y, Sakane S, Kamada Y, Murai K, Nishio A, Yamada R, Kodama T, Nozaki Y, Kakita N, Ishida H, Nakanishi F, Morishita N, Imanaka K, Sakakibara M, Tatsumi T, Miyoshi E, Takehara T. Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosis. PLoS One. 2022 Dec 21;17(12):e0279416. doi.org/10.1371/journal.pone.0279416. PMID: 36542633

4.	Seko Y, Takahashi H, Toyoda H, Hayashi H, Yamaguchi K, Iwaki M, Yoneda M, Arai T, Shima T, Fujii H, Morishita A, Kawata K, Tomita K, Kawanaka M, Yoshida Y, Ikegami T, Notsumata K, Oeda S, Kamada Y, Sumida Y, Fukushima H, Miyoshi E, Aishima S, Okanoue T, Nakajima A, Itoh Y; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Diagnostic accuracy of enhanced liver fibrosis test for nonalcoholic steatohepatitis-related fibrosis: MULTICENTER STUDY. Hepatol Res. in press doi.org/10.1111/hepr.13871

Seko Y, Takahashi H, Toyoda H, Hayashi H, Yamaguchi K, Iwaki M, Yoneda M, Arai T, Shima T, Fujii H, Morishita A, Kawata K, Tomita K, Kawanaka M, Yoshida Y, Ikegami T, Notsumata K, Oeda S, Kamada Y, Sumida Y, Fukushima H, Miyoshi E, Aishima S, Okanoue T, Nakajima A, Itoh Y; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Diagnostic accuracy of enhanced liver fibrosis test for nonalcoholic steatohepatitis-related fibrosis: MULTICENTER STUDY. Hepatol Res. in press doi.org/10.1111/hepr.13871

5.	Seko Y, Kawanaka M, Fujii H, Iwaki M, Hayashi H, Toyoda H, Oeda S, Hyogo H, Morishita A, Munekage K, Kawata K, Yamamura S, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Okanoue T, Itoh Y, Nakajima A; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD) Age-dependent effects of diabetes and obesity on liver-related events in nonalcoholic fatty liver disease: Subanalysis of CLIONE in Asia. J Gastroenterol Hepatol. 2022 Dec;37(12):2313-2320. doi: 10.1111/jgh.16019. Online ahead of print.PMID: 36198983

Seko Y, Kawanaka M, Fujii H, Iwaki M, Hayashi H, Toyoda H, Oeda S, Hyogo H, Morishita A, Munekage K, Kawata K, Yamamura S, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Okanoue T, Itoh Y, Nakajima A; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD) Age-dependent effects of diabetes and obesity on liver-related events in nonalcoholic fatty liver disease: Subanalysis of CLIONE in Asia. J Gastroenterol Hepatol. 2022 Dec;37(12):2313-2320. doi: 10.1111/jgh.16019. Online ahead of print.PMID: 36198983

6.	Kamada Y, Takahashi H, Ogawa Y, Hyogo H, Nakamura K, Yada T, Asada N, Bando T, Sawano H, Hatanaka M, Tosa T, Ando M, Hikita E, Yoshida K, Koseki M, Sumida Y, Maeda K, Fujii M, Aishima S, Hayakawa M, Nakajima A, and Japan Study group of NAFLD (JSG-NAFLD) Characterization of nutrient intake in biopsy-confirmed NAFLD patients. Nutrients 2022, 14(7), 3453. doi: 10.3390/nu14173453.

7.	Fukuoka T, Moriwaki K, Takamatsu S, Kondo J, Tanaka-Okamoto M, Tomioka A, Semba M, Komazawa-Sakon S, Kamada Y, Kaji H, Miyamoto Y, Inoue M, Bessho K, Miyoshi Y, Ozono K, Nakano H, Miyoshi E. Lewis glycosphingolipids as critical determinants of TRAIL sensitivity in cancer cells. Oncogene. 2022,Sep;41(38):4385-4396. doi: 10.1038/s41388-022-02434-3.

8.	Futani Y, Hamano M, Matsumoto R, Hashimoto S, Nishimura R, Ueda M, Arihara N, Fujii H, Ono M, Miyoshi E, Saito S, Kamada Y. Shear-wave elastography using commercially available ultrasound in a mouse model of chronic liver disease.Gastrointest Disord. 2022, 4(3):1045-1061. doi:10.3390/gidisord4030015.

9.	Kamada Y, Nakahara T, Munekage K, Fujii H, Sawai Y, Doi Y, Ono M, Hyogo H, Sumida Y, Morishita K, Asuka T, Ouchida T, Imai Y, and Miyoshi E; Japan Study Group of NAFLD (JSG-NAFLD). Serum Mac-2 binding protein level predicts the development of liver-related events and colorectal cancer in patients with nonalcoholic fatty liver disease. Hepatol Commun 2022, 6(7): 1527-1536 doi: 10.1002/hep4.1934.PMID: 35478356

Kamada Y, Nakahara T, Munekage K, Fujii H, Sawai Y, Doi Y, Ono M, Hyogo H, Sumida Y, Morishita K, Asuka T, Ouchida T, Imai Y, and Miyoshi E; Japan Study Group of NAFLD (JSG-NAFLD). Serum Mac-2 binding protein level predicts the development of liver-related events and colorectal cancer in patients with nonalcoholic fatty liver disease. Hepatol Commun 2022, 6(7): 1527-1536 doi: 10.1002/hep4.1934.PMID: 35478356

10.	Kanno K, Koseki M, Chang J, Saga A, Inui H, Okada T, Tanaka K, Asaji M, Zhu Y, Ide S, Saito S, Higo T, Okuzaki D, Kamada Y, Ono M, Saibara T, Ohama T, Nishida M, Yamashita S, Sakata Y. A Selective PPARα modulator, Pemafibrate Suppressed NLRP3 Inflammasome Activation Both in Liver and Heart in a Model of “Steatohepatitis-Related Cardiomyopathy”. Sci Rep. 2022 Feb 22;12(1):2996. doi: 10.1038/s41598-022-06542-8.

10.

Kanno K, Koseki M, Chang J, Saga A, Inui H, Okada T, Tanaka K, Asaji M, Zhu Y, Ide S, Saito S, Higo T, Okuzaki D, Kamada Y, Ono M, Saibara T, Ohama T, Nishida M, Yamashita S, Sakata Y. A Selective PPARα modulator, Pemafibrate Suppressed NLRP3 Inflammasome Activation Both in Liver and Heart in a Model of “Steatohepatitis-Related Cardiomyopathy”. Sci Rep. 2022 Feb 22;12(1):2996. doi: 10.1038/s41598-022-06542-8.

11.	Fujita S, Horitani E, Miyashita Y, Fujita Y, Fukui K, Kamada Y, Mineo I, Asano Y, Iwahashi H, Kozawa J, Shimomura I. A case of whole-exome sequencing in a Japanese patient with hyperinsulinemia and liver dysfunction. J Endocr Soc. 2022 Jan 29;6(3):bvac008. doi: 10.1210/jendso/bvac008. eCollection 2022 Mar 1.

12.	Itoyama S, Noda E, Takamatsu S, Kondo J, Kawaguchi R, Shimosaka M, Fukuoka T, Motooka D, Nakamura S, Tanemura M, Mitsufuji S, Iwagami Y, Akita H, Tobe T, Kamada Y, Eguchi H, Miyoshi E. Enterococcus spp. have higher fitness for survival, in a pH-dependent manner, in pancreatic juice among duodenal bacterial flora. JGH Open. 2022 Jan 5;6(1):85-90. doi: 10.1002/jgh3.12703. eCollection 2022 Jan.

13.	Fujii H, Nakamura N, Fukumoto S, Kimura T, Nakano A, Nadatani Y, Tauchi Y, Nishii Y, Takashima S, Kamada Y, Watanabe T, Kawada N. Lifestyle changes during the coronavirus disease 2019 pandemic impact metabolic dysfunction-associated fatty liver disease. Liver Int. 2022 May;42(5):995-1004. doi: 10.1111/liv.15158. Epub 2022 Mar 18.PMID: 34995404

14.	Moriwaki K, Park C, Koyama K, Balaji S, Kita K, Yagi R, Komazawa-Sakon S, Semba M, Asuka T, Nishiyama C, Nakano H, Kamada Y, Miyoshi E, Chan FKM. The scaffold-dependent function of RIPK1 in dendritic cells promotes injury-induced colitis. Mucosa Immunol. 2022 Jan;15(1):84-95. doi: 10.1038/s41385-021-00446-y. Epub 2021 Aug 30.PMID: 34462571

2021

1.	Kamada Y, Takahashi H, Shimizu M, Kawaguchi T, Sumida Y, Fujii H, Seko Y, Fukunishi S, Tokushige K, Nakajima A, Okanoue T; Japan Study Group of NAFLD (JSG‐NAFLD). Clinical practice advice on lifestyle modification in the management of nonalcoholic fatty liver disease in Japan: an expert review. J Gastroenterol. 2021, 56(12):1045-1061. doi: 10.1007/s00535-021-01833-9.

2.	Tokushige K, Ikejima K, Ono M, Eguchi Y, Kamada Y, Itoh Y, Akuta N, Yoneda M, Iwasa M, Yoneda M, Otsuka M, Tamaki N, Kogiso T, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. J Gastroenterol 2021, 56(11):951-963. doi: 10.1007/s00535-021-01796-x.

3.	Tokushige K, Ikejima K, Ono M, Eguchi Y, Kamada Y, Itoh Y, Akuta N, Yoneda M, Iwasa M, Yoneda M, Otsuka M, Tamaki N, Kogiso T, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. Hepatol Res 2021, 51(10):1013-1025. doi: 10.1111/hepr.13688.

4.	Tamai Y, Iwasa M, Eguchi A, Shigefuku R, Kamada Y, Miyoshi E, Takei Y. Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy. JGH Open.2021, 23;5(7):827-830. doi: 10.1002/jgh3.12596.

5.	Kimura A, Utsumi S, Shimokawa A, Nishimori R, Stewart NJ, Kamada Y, Imai H, Fujiwara H. Inflammation during Lung Cancer Progression and Ethyl Pyruvate Treatment Observed by Pulmonary Functional Hyperpolarized 129Xe MRI in Mice. Contrast Media Mol Imaging 2021: 9918702. doi: 10.1155/2021/9918702. eCollection 2021.

6.	Kozumi K, Kodama T, Murai H, Sakane S, Govaere O, Cockell S, Motooka D, Kakita N, Yamada Y, Kondo Y, Tahata Y, Yamada R, Hikita H, Sakamori R, Kamada Y, Daly AK, Anstee QM, Tatsumi T, Morii E, Takehara T. Transcriptomics Identify Thrombospondin-2 as a Biomarker for Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis. Hepatology. 2021 Jun 9. doi: 10.1002/hep.31995. Online ahead of print.

7.	Sumida, Y. Yoneda, M. Tokushige, K. Kawanaka, M. Fujii, H. Yoneda, M. Imajo, K. Takahashi, H. Eguchi, Y. Ono, M. Nozaki, Y. Hyogo, H. Koseki, M. Yoshida, Y. Kawaguchi, T. Kamada, Y. Okanoue, T. Nakajima, A. FIB-4 First in Diagnostic Algorithm of MAFLD at the Era of “Global Metabodemic“. Life. 2021; 11(2):143. doi: 10.3390/life11020143.

8.	Motooka K, Morishita K, Ito N, Shinzaki S, Tashiro T, Nojima S, Shimizu K, Date M, Sakata N, Yamada M, Takamatsu S, Kamada Y, Iijima H, Mizushima T, Morii E, Takehara T, and Miyoshi E. Detection of fucosylated haptoglobin using the 10-7G antibody as a biomarker for evaluating endoscopic remission in ulcerative colitis. World J Gastroenterol. 2021; 14;27(2):162-175. doi: 10.3748/wjg.v27.i2.162.

9.	Itoh N, Yamada M, Morishita K, Nojima S, Motooka K, Sakata N, Asuka T, Otsu R, Takamatsu S, Kamada Y, Mori S, Akita H, Eguchi H, Morii E, and Miyoshi E. Identification of fucosylated haptoglobin-producing cells in pancreatic cancer tissue and its molecular mechanism. Glycoconj J. 2021; 38(1):45-54. doi: 10.1007/s10719-020-09970-8.

10.	Chang J, Koseki M, Saga A, Kanno K, Higo H, Okuzaki D, Okada T, Inui H, Asaji M, Zhu Y, Kamada Y, Ono M, Saibara T, Ichi I, Ohama T, Nishida M, Yamashita S, Sakata Y. Dietary Oxysterol, 7-Ketocholesterol, Accelerates Hepatic Lipid Accumulation and Macrophage Infiltration in Obese Mice. Front Endocrinol 11:614692. doi: 10.3389/fendo.2020.614692. eCollection 2020

2020

1.	Takahashi, H., Nakahara, T., Kogiso, T., Imajo, K., Kessoku, T., Kawaguchi, T., Ide, T., Kawanaka, M., Hyogo, H., Fujii, H., Ono, M., Kamada, Y., Sumida, Y., Anzai, K., Shimizu, M., Torimura, T., Nakajima, A., Tokushige, K., Chayama, K., Eguchi, Y. Japan Study Group of NAFLD (JSG-NAFLD). Eradication of hepatitis C virus with direct‐acting antivirals improves glycemic control in diabetes: A multicenter study. JGH Open. 2020;19;5(2):228-234. doi: 10.1002/jgh3.12474.

Takahashi, H., Nakahara, T., Kogiso, T., Imajo, K., Kessoku, T., Kawaguchi, T., Ide, T., Kawanaka, M., Hyogo, H., Fujii, H., Ono, M., Kamada, Y., Sumida, Y., Anzai, K., Shimizu, M., Torimura, T., Nakajima, A., Tokushige, K., Chayama, K., Eguchi, Y. Japan Study Group of NAFLD (JSG-NAFLD). Eradication of hepatitis C virus with direct‐acting antivirals improves glycemic control in diabetes: A multicenter study. JGH Open. 2020;19;5(2):228-234. doi: 10.1002/jgh3.12474.

2.	Kamada Y, Morishita K, Koseki M, Nishida M, Asuka T, Naito Y, Yamada M, Takamatsu S, Sakata Y, Takehara T, Miyoshi E. Serum Mac-2 Binding Protein Levels Associate with Metabolic Parameters and Predict Liver Fibrosis Progression in Subjects with Fatty Liver Disease: A 7-Year Longitudinal Study. Nutrients 12(6):E1770. doi: 10.3390/nu12061770., 2020

3.	Iwaki A, Sobajima T, Moriwaki K, Taniguchi M, Yoshimura S, Kunio M, Kamada Y, Miyoshi E, and Harada A. Loss of Rab6a in the small intestine causes lipid accumulation and epithelial cell death from lactation. FASEB J. 34(7):9450-9465. doi: 10.1096/fj.202000028R.

4.	Kamada Y, Yamamoto A, Fujiyoshi A, Koseki M, Morishita K, Asuka T, Takamatsu S, Sakata Y, Takehara T, Taniguchi N, and Miyoshi E. Loss of core fucosylation reduces low-density lipoprotein receptor expression in hepatocytes by inducing PCSK9 production. Biochem Biophys Res Commun. 2020; 527(3):682-688 doi: 10.1016/j.bbrc.2020.05.019

5.	Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M, Imajo K, Takahashi H, Eguchi Y, Ono M, Nozaki Y, Hyogo H, Koseki M, Yoshida Y, Kawaguchi T, Kamada Y, Okanoue T, Nakajima A, Atsushi Nakajima; Japan Study Group of NAFLD (JSG-NAFLD). Antidiabetic therapy in the treatment of nonalcoholic steatohepatitis. Inter J Mol Sci 2020;21 (6),1907. doi: 10.3390/ijms21061907

Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M, Imajo K, Takahashi H, Eguchi Y, Ono M, Nozaki Y, Hyogo H, Koseki M, Yoshida Y, Kawaguchi T, Kamada Y, Okanoue T, Nakajima A; Japan Study Group of NAFLD (JSG-NAFLD). Estimated Prevalence of Advanced Hepatic Fibrosis by Elastography in Patients with Type 2 Diabetes. Interventions Obes Diabetes 3(3). IOD.000570.2020. doi: 10.31031/IOD.2020.03.000570

7.	Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M, Imajo K, Takahashi H, Eguchi Y, Ono M, Nozaki Y, Hyogo H, Koseki M, Yoshida Y, Kawaguchi T, Kamada Y, Okanoue T, Nakajima A; Japan Study Group of NAFLD (JSG-NAFLD). Antidiabetic Treatments for Diabetes with Liver Cirrhosis. Interventions Obes Diabetes 3(3). IOD.000566.2020. doi: 10.31031/IOD.2020.03.000566

8.	Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M, Imajo K, Takahashi H, Eguchi Y, Ono M, Nozaki Y, Hyogo H, Koseki M, Yoshida Y, Kawaguchi T, Kamada Y, Okanoue T, Nakajima A; Japan Study Group of NAFLD (JSG-NAFLD). Hepatoprotective Effect of SGLT2 Inhibitor on Nonalcoholic Fatty Liver Disease. Diab Res. 2020 Mar 05;2(S1):17-25.

9.	Morishita K, Morishita K, Maki Y, Takamatsu S, Ito N, Koda S, Motooka K, Kamada Y, Kajihara Y, Miyoshi E. Identification of the epitope of 10-7G glycan antibody to recognize cancer-associated haptoglobin. Anal Biochem. 2020 Jan 22:113588. doi:10.1016/j.ab.2020.113588.

10.	Miyoshi E, Kamada Y, Suzuki T. Functional glycomics: application to medical science and hepatology. Hepatol Res; Feb;50(2):153-164. doi: 10.1111/hepr.13459. 2020

11.

Kurahashi T, Yoshida Y, Ogura S, Egawa M, Furuta K, Hikita H, Kodama T, Sakamori R, Kiso S, Kamada Y, Wang IC, Eguchi H, Morii E, Doki Y, Mori M, Kalinichenko VV, Tatsumi T, Takehara T. Forkhead Box M1 transcription factor drives liver inflammation linking to hepatocarcinogenesis in mice. Cell Mol Gastroenterol Hepatol. 2020;9(3):425-446 Oct 24. pii: S2352-345X(19)30144-4. doi: 10.1016/j.jcmgh.2019.10.008.

12.

Fujihira H, Masahara-Negishi Y, Akimoto Y, Hirayama H, Lee HC, Story BA, Mueller WF, Jakob P, Clauder-Münster S, Steinmetz LM, Radhakrishnan SK, Kawakami H, Kamada Y, Miyoshi E, Yokomizo T, Suzuki T. Liver-specific deletion of Ngly1 causes abnormal nuclear morphology and lipid metabolism under food stress. Biochim Biophys Acta Mol Basis Dis. 2020 Mar 1;1866(3):165588. doi: 10.1016/j.bbadis.2019.165588.

2019

1.	Manabe Y, Marchetti R, Takakura Y, Nagasaki M, Nihei W, Takebe T, Tanaka K, Kabayama K, Chiodo F, Hanashima S, Kamada Y, Miyoshi E, Dulal HP, Yamaguchi Y, Adachi Y, Ohno N, Tanaka H, Silipo A, Fukase K, Molinaro A. The core fucose on an IgG antibody is an endogenous ligand of Dectin-1. Angew Chem Int Ed Engl. 2019; 58(51):18697-18702.

2.	Egashira Y, Suganuma M, Kataoka Y, Higa Y, Ide N, Morishita K, Kamada Y, Gu J, Fukagawa K, Miyoshi E. Establishment and characterization of a fucosylated α-fetoprotein-specific monoclonal antibody: a potential application for clinical research. Sci Rep. 2019 Aug 26;9(1):12359

3.	Sumida Y, Kamada Y, Iwai M, Kwo PY, Yoneda M. Diagnosis of Liver Diseases 2nd edition p. 19-34 (total 304 pages) 2019 Laboratory tests in liver diseases.

4.	Fujii M, Ohno Y, Yamada M, Kamada Y, Miyoshi E. Impact of fatty pancreas and lifestyle on the development of subclinical chronic pancreatitis in healthy people undergoing a medical checkup. Environmental Health and Preventive Medicine 2019; 24(1):10. doi:10.1186/s12199-019-0763-2.

Kodama K, Kawaguchi T, Hyogo H, Nakajima T, Ono M, Seike M, Takahashi H, Nozaki Y, Kawanaka M, Tanaka S, Imajo K, Sumida Y, Kamada Y, Fujii H, Seko Y, Takehara T, Itoh Y, Nakajima A, Masaki N, Torimura T, Saibara T, Karino Y, Chayama K, Tokushige K. Clinical features of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without advanced fibrosis. J Gastroenterol Hepatol. 2019; 34(9); 1626-32; Jan 22. doi: 10.1111/jgh.14608. [Epub ahead of print] PMID: 30668889

6.	Nakayama K, Wakamatsu K, Fujii H, Shinzaki S, Takamatsu S, Kitazume S, Kamada Y, Takehara T, Taniguchi N, Miyoshi E. Core fucose is essential glycosylation for CD14-dependent Toll-like receptor 4 and Toll-like receptor 2 signaling in macrophages. J Biochem.: 165(3): 227-237, 2019 doi: 10.1093/jb/mvy098.

2018

Maekawa T, Fukaya R, Takamatsu S, Itoyama S, Fukuoka T, Yamada M, Hata T, Nagaoka S, Kawamoto K, Eguchi H, Murata K, Kumada T, Ito T, Tanemura M, Fujimoto K, Tomita Y, Tobe T, Kamada Y, Miyoshi E. Possible involvement of Enterococcus infection in the pathogenesis of chronic pancreatitis and cancer. Biochem Biophys Res Commun. 2018 Dec 2;506(4):962-969. doi: 10.1016/j.bbrc.2018.10.169. Epub 2018 Nov 3.PMID:30401562

2.	Morishita K, Ito N, Koda S, Maeda M, Nakayama K, Yoshida K, Takamatsu S, Yamada M, Eguchi H, Kamada Y, Miyoshi E. Haptoglobin phenotype is a critical factor in the use of fucosylated haptoglobin for pancreatic cancer diagnosis. Clin Chim Acta. 2018 Dec;487:84-89. doi: 10.1016/j.cca.2018.09.001. Epub 2018 Sep 3.PMID:30189188

Kawaguchi T, Tokushige K, Hyogo H, Aikata H, Nakajima T, Ono M, Kawanaka M, Sawada K, Imajo K, Honda K, Takahashi H, Mori K, Tanaka S, Seko Y, Nozaki Y, Kamada Y, Fujii H, Kawaguchi A, Takehara T, Yanase M, Sumida Y, Eguchi Y, Seike M, Yoneda M, Suzuki Y, Saibara T, Karino Y, Chayama K, Hashimoto E, George J, Torimura T. A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD. Sci Rep. 2018. Jul 11;8(1):10434. doi: 10.1038/s41598-018-28650-0.PMID:29992975

4.	Ogura S, Yoshida Y, Kurahashi T, Egawa M, Furuta K, Kiso S, Kamada Y, Hikita H, Eguchi H, Ogita H, Doki Y, Mori M, Tatsumi T, Takehara T. Targeting the mevalonate pathway is a novel therapeutic approach to inhibit oncogenic FoxM1 transcription factor in human hepatocellular carcinoma. Oncotarget: 9(30):21022-21035., 2018

5.	Nishino K, Koda S, Kataoka N, Takamatsu S, Nakano M, Ikeda S, Kamamatsu Y, Morishita K, Moriwaki K, Eguchi H, Yamamoto E, Kikkawa F, Tomita Y, Kamada Y, Miyoshi E. Establishment of an antibody specific for cancer-associated haptoglobin: A possible implication of clinical investigation. Oncotarget: 9(16): 12732-12744, 2018

2017

1.	Hata T, Kawamoto K, Eguchi H, Kamada Y, Takamatsu S, Maekawa T, Nagaoka S, Yamada D, Iwagami Y, Asaoka T, Noda T, Wada H, Gotoh K, Masamune A, Miyoshi E, Mori M, Doki Y. Fatty Acid-Mediated Stromal Reprogramming of Pancreatic Stellate Cells Induces Inflammation and Fibrosis That Fuels Pancreatic Cancer. Pancreas;46(10):1259-1266, 2017

2.	Kamada Y and Miyoshi E. Mac-2 binding protein is a useful liver fibrosis biomarker for NAFLD/NASH. TIGG (Trends in Glycoscience and Glycotechnology); 29: E85-E92, 2017

3.	Kamada Y, Ono M, Hyogo H, Fujii H, Sumida Y, Yamada M, Mori K, Tanaka S, Maekawa T, Ebisutani Y, Yamamoto A, Takamatsu S, Yoneda M, Kawada N, Chayama K, Saibara T, Takehara T, Miyoshi E.; Japan Study Group of NAFLD (JSG-NAFLD), Use of Mac-2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis. Hepatol Commun; 1(8): 780-791, 2017

4.	Kusama K, Okamoto Y, Saito K, Kasahara T, Murata T, Ueno Y, Kobayashi Y, Kamada Y, Miyoshi E. Reevaluation of Pholiota squarrosa lectin-reactive haptoglobin as a pancreatic cancer biomarker using an improved ELISA system. Glycoconj J; 34(4):537-544, 2017

5.	Ito K, Murotani K, Nakade Y, Inoue T, Nakao H, Sumida Y, Kamada Y, Yoneda M. Serum WFA+ -M2BP levels predict liver fibrosis, development of hepatocellular carcinoma, and overall survival: A meta-analysis. J Gastroenterol Hepatol ;32(12):1922-1930, 2017

6.	Shinzaki S, Iijima H, Fujii H, Kamada Y, Naka T, Takehara T, Miyoshi E. A novel pathogenesis of inflammatory bowel disease from the perspective of glyco-immunology. J Biochem;161(5):409-415, 2017

7.	Manabe Y, Kasahara S, Takakura Y, Yang X, Takamatsu S, Kamada Y, Miyoshi E, Yoshidome D, Fukase K. Development of α1,6-fucosyltransferase inhibitors through the diversity-oriented syntheses of GDP-fucose mimics using the coupling between alkyne and sulfonyl azide. Bioorganic & Medicinal Chemistry; 25(11):2844-2850, 2017

8.	Egawa M, Yoshida Y, Ogura S, Kurahashi T, Kizu T, Furuta K, Kamada Y, Chatani N, Hamano M, Kiso S, Hikita H, Tatsumi T, Eguchi H, Nagano H, Doki Y, Mori M, Takehara T. Increased FoxM1 expression is associated with clinicopathological features and confers a poor prognosis in human hepatocellular carcinoma. Hepatol Res 47(11):1196-1205, 2017

9.	Kamada Y, Kida S, Hirano KI, Yamaguchi S, Suzuki A, Hashimoto C, Kimura A, Sato M, Fujii H, Sobajima T, Yamamoto A, Ebisutani Y, Takamatsu S, Shinzaki S, Yoshida Y, Yamada M, Nagasaka H, Takehara T, Miyoshi E. Hepatic aberrant glycosylation by N-acetylglucosaminyltransferase V accelerates HDL assembly. Am J Physiol Gastrointest Liver Physiol.; 311(5):G859-G868, 2016

10.	Iwata A, Kamada Y(equally contributed), Ebisutani Y, Yamamoto A, Ueda Y, Arai H, Fujii H, Takamatsu S, Maruyama N, Maeda M, Takehara T, Miyoshi E. Establishment of mouse Mac-2 binding protein enzyme-linked immunosorbent assay and its application for mouse chronic liver disease models. Hepatol Res; 47(9):902-909, 2017

2016

1.	Miyoshi E, Kamada Y. Application of glyco-science to the early detection of pancreatic cancer. Cancer Sci; 107(10):1357-1362, 2016

2.	Takamatsu S, Shimomura M, Kamada Y, Maeda H, Sobajima T, Hikita H, Iijima M, Okamoto Y, Misaki R, Fujiyama K, Nagamori S, Kanai Y, Takehara T, Ueda K, Kuroda S, Miyoshi E. Core-fucosylation plays a pivotal role in hepatitis B pseudo virus infection: a possible implication for HBV glyco-therapy. Glycobiology; 26(11):1180-1189, 2016

3.	Maekawa T, Kamada Y (equally contributed), Ebisutani Y, Ueda M, Hata T, Kawamoto K, Takamatsu S, Mizutani K, Shimomura M, Sobajima T, Fujii H, Nakayama K, Nishino K, Yamada M, Kumada T, Ito T, Eguchi H, Nagano H, Miyoshi E. Serum Mac-2 binding protein is a novel biomarker for chronic pancreatitis. World J Gastroenterol; 22(17):4403-10, 2016

4.	Fujii H, Shinzaki S, Iijima H, Wakamatsu K, Iwamoto C, Sobajima T, Kuwahara R, Hiyama S, Hayashi Y, Takamatsu S, Uozumi N, Kamada Y, Tsujii M, Taniguchi N, Takehara T, Miyoshi E. Core Fucosylation on T cells, Required for Activation of T-cell Receptor Signaling and Induction of Colitis in Mice, is Increased in Patients with Inflammatory Bowel Disease. Gastroenterology; 150(7): 1620-32, 2016

5.	Sawanobori A, Moriwaki K, Takamatsu S, Kamada Y, Miyoshi E. A glycoproteomic approach to identify novel glycomarkers for cancer stem cells. Proteomics; 16(24):3073-3080, 2016

6.	Kamada Y, Hashimoto R, Yamamori H, Yasuda Y, Takehara T, Fujita Y, Hashimoto K, Miyoshi E. Impact of plasma transaminase levels on the peripheral blood glutamate levels and memory functions in healthy subjects. BBA Clin.; 5:101-7, 2016

7.	Takahashi S, Sugiyama T, Shimomura M, Kamada Y, Fujita K, Nonomura N, Miyoshi E, Nakano M. Site-specific and linkage analyses of fucosylated N-glycans on haptoglobin in sera of patients with various types of cancer: possible implication for the differential diagnosis of cancer. Glycoconj J; 33(3): 471-82, 2016

8.	Ueda M, Kamada Y (equally contributed), Takamatsu S, Shimomura M, Maekawa T, Sobajima T, Fujii H, Nakayama K, Nishino K, Yamada M, Kobayashi Y, Kumada T, Ito T, Eguchi H, Nagano H, Miyoshi E. Specific increase in serum core-fucosylated haptoglobin in patients with chronic pancreatitis. Pancreatology 16(2):238-43, 2016

9.	Furuta K, Yoshida Y, Ogura S, Kurahashi T, Kizu T, Maeda S, Egawa M, Chatani N, Nishida K, Nakaoka Y, Kiso S, Kamada Y, Takehara T. Gab1 adaptor protein acts as a gatekeeper to balance hepatocyte death and proliferation during acetaminophen-induced liver injury in mice. Hepatology;63(4):1340-55, 2016

10.	Tanaka-Okamoto M, Yabu M, Mukai M, Takahashi H, Fujiwara Y, Ohue M, Kamada Y, Miyoshi E, and Miyamoto Y. Elevation of CA19-9 related novel marker, Core 1 Sialyl Lewis A, in sera of adenocarcinoma patients verified by a SRM based method. J Proteome Res; 15(1): 152-65, 2016

11.

Tokushige K, Hyogo H, Nakajima T, Ono M, Kawaguchi T, Honda K, Eguchi Y, Nozaki Y, Kawanaka M, Tanaka S, Imajo K, Sumida Y, Kamada Y, Fujii H, Suzuki Y, Kogiso T, Karino Y, Munekage K, Kuromatsu R, Oeda S, Yanase M, Mori K, Ogawa Y, Seko Y, Takehara T, Itoh Y, Nakajima A, Kanemasa K, Nishino K, Masaki N, Takahashi H, Seike M, Torimura T, Saibara T, Toyota J, Chayama K, Hashimoto E. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey. J Gastroenterol; 51(6): 586-96, 2016

12.	Miyoshi E, Shinzaki S, Fujii H, Iijima H, Kamada Y, Takehara T. Role of aberrant IgG glycosylation in the pathogenesis of inflammatory bowel disease. Proteomics Clin Appl; 10(4): 384-90, 2016

13.	Shinzaki S, Ishii M, Fujii H, Iijima H, Wakamatsu K, Kawai S, Shiraishi E, Hiyama S, Inoue T, Hayashi Y, Kuwahara R, Takamatsu S, Kamada Y, Morii E, Tsujii M, Takehara T, Miyoshi E. N-Acetylglucosaminyltransferase V exacerbates murine colitis with macrophage dysfunction and enhances colitic tumorigenesis. J Gastroenterol;51(4):357-69, 2016

14.	Kamada Y, Ono M, Hyogo H, Fujii H, Sumida Y, Mori K, Tanaka S, Yamada M, Akita M, Mizutani K, Fujii H, Yamamoto A, Takamatsu S, Yoshida Y, Itoh Y, Kawada N, Chayama K, Saibara T, Takehara T, Miyoshi E. A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers. Hepatology; 62(5): 1433-43, 2015

15.	Kamada Y, Ebisutani Y (equally contributed), Kida S, Mizutani K, Akita M, Yamamoto A, Fujii H, Sobajima T, Terao N, Takamatsu S, Yoshida Y, Takehara T, Miyoshi E. Ectopic expression of N-acetylglucosaminyl transferase V (GnT-V) accelerates hepatic triglyceride synthesis. Hepatol Res; 46(3): E118-29, 2016

2015

1.	Shimomura M, Nakayama K, Azuma K, Terao N, Nishino K, Takamatsu S, Nakano M, Takahashi S, Kobayashi Y, Murata K, Kamada Y, Miyoshi E. Establishment of a novel lectin-antibody ELISA system to determine core-fucosylated haptoglobin. Clin Chim Acta; 446: 30-6, 2015

2.	Kamada Y, Miyoshi E. Value of Fetuin-A as a Predictor of Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Author's reply. Liver Int; 35(8): 2062, 2015

3.	Wang Y, Fukuda T, Isaji T, Lu J, Gu W, Lee HH, Ohkubo Y, Kamada Y, Taniguchi N, Miyoshi E, Gu J. Loss of α1,6-fucosyltransferase suppressed liver regeneration: implication of core fucose in the regulation of growth factor receptor-mediated cellular signaling. Sci Rep; 5: 925-35, 2015

4.	Miyoshi E and Kamada Y, 2015/1/1, LXII, 1568 p. Springer

5.	Kizu T, Yoshida Y, Furuta K, Ogura S, Egawa M, Chatani N, Hamano M, Takemura T, Ezaki H, Kamada Y, Nishida K, Nakaoka Y, Kiso S, Takehara T. Loss of Gab1 adaptor protein in hepatocytes aggravates experimental liver fibrosis in mice. Am J Physiol Gastrointest Liver Physiol ; 308(7): G613-24, 2015

6.	Terao N, Takamatsu S, Minehira T, Sobajima T, Nakayama K, Kamada Y, Miyoshi E. Fucosylation is common type of glycosylation in pancreatic cancer stem cell-like phenotypes. World J Gastroenterol; 21(13): 3876-87, 2015

7.	Chatani N, Kamada Y, Kizu T, Ogura S, Furuta K, Egawa M, Hamano M, Ezaki H, Kiso S, Shimono A, Ouchi N, Yoshida Y, Takehara T. Secreted frizzled-related protein 5 (Sfrp5) decreases hepatic stellate cell activation and liver fibrosis. Liver Int ;35(8):2017-26, 2015

8.	Kamada Y, Sato M, Kida S, Akita M, Mizutani K, Fujii H, Sobajima T, Yoshida Y, Shinzaki S, Takamatsu S, Takehara T, Miyoshi E. N-Acetylglucosaminyltransferase V exacerbates concanavalin A-induced mouse hepatitis. Mol Med Rep;11(5):3573-84, 2015

9.	Asazawa H, Kamada Y (equally contributed), Takeda Y, Takamatsu S, Shinzaki S, Kim Y, Nezu R, Kuzushita N, Mita E, Kat M, Miyoshi E. Serum fucosylated haptoglobin in chronic liver diseases as a potential biomarker of hepatocellular carcinoma development. Clin Chem Lab Med ;53(1):95-102, 2015

10.	Kamada Y, Sato M (equally contributed), Takeda Y, Kida S, Ohara Y, Fujii H, Akita M, Mizutani K, Yoshida Y, Yamada M, Hougaku H, Takehara T, Miyoshi E. Fetuin-A negatively correlates with liver and vascular fibrosis in nonalcoholic fatty liver disease subjects. Liver Int ;35(3):925-35, 2015

2014

1.	Azuma K, Serada S, Takamatsu S, Terao N, Takeishi S, Kamada Y, Naka T, Miyoshi E　Identification of sialylated glycoproteins in doxorubicin-treated hepatoma cells with glycoproteomic analyses. J Proteome Res ;13(11):4869-77, 2014

2.	Tomita Y, Azuma K, Nonaka Y, Kamada Y, Tomoeda M, Kishida M, Tanemura M, Miyoshi E. Pancreas Fatty Degeneration and Fibrosis as Predisposing Factors of Pancreatic Ductal Adenocarcinoma Development. Pancreas ;43(7):1032-41, 2014

3.	Azuma K, Shinzaki S, Asazawa H, Kuroki E, Kawamoto S, Kamada Y, Hayakawa K, Miyoshi E. Twin studies on the effect of genetic factors on serum agalactosyl immunoglobulin G levels. Biomed Rep ;2(2):213-16, 2014

4.	Hamano M, Ezaki H, Kiso S, Furuta K, Egawa M, Kizu T, Chatani N, Kamada Y, Yoshida Y, Takehara T. Lipid overloading during liver regeneration causes delayed hepatocyte DNA replication by increasing ER stress in mice with simple hepatic steatosis. J Gastroenterol 49(2):305-16, 2014

5.	Wang X, Sugimoto K, Fujisawa T, Shindo N, Minato S, Kamada Y, Hamano M, Ohishi M, Ikegami H, Rakugi H.Novel effect of ezetimibe to inhibit the development of non-alcoholic fatty liver disease in Fatty Liver Shionogi mouse. Hepatol Res 44(1):102-13, 2014

2013

1.	Nakayama K, Moriwaki K, Imai T, Shinzaki S, Kamada Y, Murata K, Miyoshi E. Mutation of GDP-Mannose-4,6-Dehydratase in Colorectal Cancer Metastasis. PLoS One ;29;8(7):e70298, 2013

2.	Kamada Y, Akita M, Takeda Y, Yamada S, Fujii H, Sawai Y, Doi Y, Asazawa H, Nakayama K, Mizutani K, Fujii H, Yakushijin T, Miyazaki M, Ezaki H, Hiramatsu N, Yoshida Y, Kiso S, Imai Y, Kawada N, Takehara T, Miyoshi E. Serum fucosylated haptoglobin as a novel diagnostic biomarker for predicting hepatocyte ballooning and nonalcoholic steatohepatitis. PLoS One ;Jun 21;8(6):e66328, 2013

Kamada Y, Fujii H, Fujii H, Sawai Y, Doi Y, Uozumi N, Mizutani K, Akita M, Sato M, Kida S, Kinoshita N, Matuyama N, Yakushijin T, Miyazaki M, Ezaki H, Hiramatsu N, Yoshida Y, Kiso S, Imai Y, Kawada N, Takehara T, Miyoshi E. Serum Mac-2 binding protein levels as a novel diagnostic biomarker for prediction of disease severity and nonalcoholic steatohepatitis. Proteomics Clin Appl ;7(9-10):648-56, 2013

4.	Takemura T, Yoshida Y, Kiso S, Kizu T, Furuta K, Ezaki H, Hamano M, Egawa M, Chatani N, Kamada Y, Imai Y, Higashiyama S, Iwamoto R, Mekada E, Takehara T. Conditional loss of heparin-binding EGF-like growth factor results in enhanced liver fibrosis after bile duct ligation in mice. Biochem Biophys Res Commun 437(2):185-91, 2013

5.	Kamada Y, Kinoshita N, Tsuchiya Y, Kobayashi K, Fujii H, Terao N, Kamihagi K, Koyama N, Yamada S, Daigo Y, Nakamura Y, Taniguchi N, Miyoshi E. Reevaluation of a lectin antibody ELISA kit for measuring fucosylated haptoglobin in various conditions. Clin Chim Acta 417:48-53, 2013

6.	Shinzaki S, Kuroki E, Iijima H, Tatsunaka N, Ishii M, Fujii H, Kamada Y, Kobayashi T, Shibukawa N, Inoue T, Tsujii M, Takeishi S, Mizushima T, Ogata A, Naka T, Plevy SE, Takehara T, Miyoshi E. Lectin-based Immunoassay for Aberrant IgG Glycosylation as the Biomarker for Crohn's Disease. Inflamm Bowel Dis 19(2): 321-31, 2013

7.	Kamada Y, Kiso S, Yoshida Y, Chatani N, Kizu T, Hamano M, Egawa M, Takemura T, Ezaki H, Furuta K, Hayashi N, Takehara T. Pitavastatin ameliorated the progression of steatohepatitis in ovariectomized mice fed high fat and high cholesterol diet. Hepatol Res 43(4):401-12, 2013

8.	Takemura T, Yoshida Y, Kiso S, Saji Y, Ezaki H, Hamano M, Kizu T, Egawa M, Chatani N, Furuta K, Kamada Y, Iwamoto R, Mekada E, Higashiyama S, Hayashi N, Takehara T. Conditional knockout of heparin-binding epidermal growth factor-like growth factor in the liver accelerates carbon tetrachloride-induced liver injury in mice. Hepatol Res 43(4):384-93, 2013

Hamano M, Kamada Y, Kiso S, Furuta K, Kizu T, Chatani N, Egawa M, Takemura T, Ezaki H, Yoshida Y, Watabe K, Hamasaki T, Umeda M, Furubayashi A, Kinoshita K, Kishida O, Fujimoto T, Yamada A, Tsukamoto Y, Tsutsui S, Takehara T, Hayashi N, Matsuzawa Y. Adiponectin negatively correlates with alcoholic and non-alcoholic liver dysfunction: Health check-up study of Japanese men. Hepatol Res 43(3): 238-48, 2013

2012

1.	Miyoshi E, Terao M, Kamada Y. Physiological roles of N-acetylglucosaminyltransferase V (GnT-V) in mice. BMB Rep 45(10):554-9, 2012

2.	Nakagawa T, Moriwaki K, Terao N, Nakagawa T, Miyamoto Y, Kamada Y, Miyoshi E. Analysis of polarized secretion of fucosylated alpha-fetoprotein in HepG2 cells. J Proteome Res 11(5):2798-806, 2012

3.	Yamamoto S, Watabe K, Araki H, Kamada Y, Kato M, Kizu T, Kiso S, Tsutsui S, Tsujii M, Kihara S, Funahashi T, Shimomura I, Hayashi N, Takehara T. Protective role of adiponectin against ethanol-induced gastric injury in mice. Am J Physiol Gastrointest Liver Physiol 302(8):G773-80, 2012

4.	Miyoshi E, Moriwaki K, Terao N, Tan CC, Terao M, Nakagawa T, Matsumoto H, Shinzaki S, Kamada Y. Fucosylation Is a Promising Target for Cancer Diagnosis and Therapy. Biomolecules 2(1):34-45, 2012

5.	Kamada Y, Mori K, Matsumoto H, Kiso S, Yoshida Y, Shinzaki S, Hiramatsu N, Ishii M, Moriwaki K, Kawada N, Takehara T, Miyoshi E. N-Acetylglucosaminyltransferase V regulates TGF-β response in hepatic stellate cells and the progression of steatohepatitis. Glycobiology 22(6):778-87, 2012

2011

1.	Kamada Y, Kiso S, Yoshida Y, Chatani N, Kizu T, Hamano M, Tsubakio M, Takemura T, Ezaki H, Hayashi N, Takehara T. Estrogen deficiency worsens steatohepatitis in mice fed high fat and high cholesterol diet. Am J Physiol Gastrointest Liver Physiol 301(6):G1031-43, 2011

2.	Kato M, Watabe K, Hamasaki T, Umeda M, Furubayashi A, Kinoshita K, Kishida O, Fujimoto T, Yamada A, Tsukamoto Y, Yamamoto S, Kamada Y, Yoshida Y, Kiso S, Tsutsui S, Kihara S, Hayashi N, Matsuzawa Y. Association of low serum adiponectin levels with erosive esophagitis in men: an analysis of 2405 subjects undergoing physical check-ups. J Gastroenterol 46(12):1361-7, 2011

3.	Terao M, Ishikawa A, Nakahara S, Kimura A, Kato A, Moriwaki K, Kamada Y, Murota H, Taniguchi N, Katayama I, Miyoshi E. Enhanced epithelial-mesenchymal transition-like phenotype in N-acetylglucosaminyltransferase V transgenic mouse skin promotes wound healing. J Biol Chem 286(32):28303-11, 2011

4.	Yamamoto S, Watabe K, Tsutsui S, Kiso S, Hamasaki T, Kato M, Kamada Y, Yoshida Y, Kihara S, Umeda M, Furubayashi A, Kinoshita K, Kishida O, Fujimoto T, Yamada A, Tsukamoto Y, Hayashi N, Matsuzawa Y. Lower serum level of adiponectin is associated with increased risk of endoscopic erosive gastritis. Dig Dis Sci 56(8):2354-60, 2011

2010

1.	Ogiyama H, Kamada Y, Kiso S, Araki H, Yamada T, Nishihara T, Watabe K, Tochino Y, Kihara S, Funahashi T, Kanno K, Shimomura I, Tsutsui S, Tazuma S, Hayashi N. Lack of adiponectin promotes formation of cholesterol gallstones in mice. Biochem Biophys Res Commun 399(3):352-8, 2010

2.	Yamada T, Araki H, Watabe K, Kamada Y, Kiso S, Ogiyama H, Nishihara T, Kihara S, Funahashi T, Shimomura I, Tsutsui S, Hayashi N. Adiponectin deficiency enhanced the severity of cerulein-induced chronic pancreatitis in mice. J Gastroenterol 45(7):742-9, 2010

2009

1.	Fukushima J, Kamada Y, Matsumoto H, Yoshida Y, Ezaki H, Takemura T, Igura T, Tsutsui S, Kihara S, Funahashi T, Shimomura I, Tamura S, Kiso S, Hayashi N. Adiponectin prevents progression of steatohepatitis in mice by regulating oxidative stress and Kupffer cell phenotype polarization. Hepatol Res 39(7):724-38, 2009

2.	Kamada Y, Nakamura T, Funahashi T, Ryo M, Nishizawa H, Okauchi Y, Fukushima J, Yoshida Y, Kiso S, Shimomura I, Hayashi N. Visceral obesity and hypoadiponectinemia are significant determinants of hepatic dysfunction. An epidemiological study of 3,827 Japanese subjects. J Clin Gastroenterol 43(10):995-1000, 2009

3.	Kamada Y, Yoshida Y, Saji Y, Fukushima J, Tamura S, Kiso S, Hayashi N. Transplantation of basic fibroblast growthfactor-pretreated adipose tissue-derived stromal cells enhances regression of liver fibrosis in mice. Am J Physiol Gastrointest Liver Physiol 296(2):157-67, 2009

4.	Ezaki H, Yoshida Y, Saji Y, Takemura T, Fukushima J, Matsumoto H, Kamada Y, Wada A, Igura T, Kihara S, Funahashi T, Shimomura I, Tamura S, Kiso S, Hayashi N. Delayed liver regeneration after partial hepatectomy in adiponectin knockout mice. Biochem Biophys Res Commun 378(1):68-72, 2009

2008

1.	Kamada Y, Takehara T, Hayashi N. Adipocytokines and liver disease. J Gastroenterol 43:811-22, 2008

2.	Araki H, Nishihara T, Matsuda M, Fukuhara A, Kihara S, Funahashi T, Kataoka TR, Kamada Y, Kiyohara T, Tamura S, Hayashi N, Shimomura I. Adiponectin plays a protective role in caerulein-induced acute pancreatitis in high-fat diet-fed mice. Gut 57(10):1431-40, 2008

2007

1.	Kamada Y, Matsumoto H, Tamura S, Fukushima J, Kiso S, Fukui K, Igura T, Maeda N, Kihara S, Funahashi T, Matsuzawa Y, Shimomura I, Hayashi N. Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J Hepatol 47(4):556-64, 2007

2.	Fukui K, Tamura S, Wada A, Kamada Y, Igura T, Kiso S, Hayashi N. Expression of Rab5a in hepatocellular carcinoma: Possible involvement in epidermal growth factor signaling. Hepatol Res 37(11):957-65, 2007

2006

1.	Fukui K, Tamura S, Wada A, Kamada Y, Sawai Y, Imanaka K, Kudara T, Shimomura I, Hayashi N. Expression and prognostic role of RhoA GTPases in hepatocellular carcinoma. J Cancer Res Clin Oncol 132(10):627-33, 2006

2.	Ujiie H, Oritani K, Kato H, Yokota T, Takahashi I, Maeda T, Masaie H, Ichii M, Kamada Y, Tamura S, Kihara S, Funahashi T, Tomiyama Y, Kanakura Y. Identification of amino-terminal region of adiponectin as a physiologically functional domain. J Cell Biochem 98(1):194-207, 2006

3.	Matsumoto H, Tamura S, Kamada Y, Kiso S, Fukushima J, Wada A, Maeda N, Kihara S, Funahashi T, Matsuzawa Y, Shimomura I, Hayashi N. Adiponectin deficiency exacerbates lipopolysaccharide/D-galactosamine-induced liver injury in mice. World J Gastroenterol 12(21):3352-8, 2006

2005

1.	Kawasaki T, Tamura S, Kiso S, Doi Y, Yoshida Y, Kamada Y, Saeki A, Saji Y, Matsuzawa Y. Effects of growth factors on the growth and differentiation of mouse fetal liver epithelial cells in primary cultures. J Gastroenterol Hepatol 20(6):857-64, 2005

2004

1.	Saji Y, Tamura S, Yoshida Y, Kiso S, Iizuka AS, Matsumoto H, Kawasaki T, Kamada Y, Matsuzawa Y, Shinomura Y. Basic fibroblast growth factor promotes the trans-differentiation of mouse bone marrow cells into hepatic lineage cells via multiple liver-enriched transcription factors. J Hepatol 41(4):545-50, 2004

2003

1.	Kamada Y, Tamura S, Kiso S, Fukui K, Doi Y, Ito N, Terui Y, Saito T, Watanabe H, Togashi H, Kawata S, Matsuzawa Y. Angiotensin II stimulates the nuclear translocation of Smad2 and induces PAI-1mRNA in rat hepatic stellate cells. Hepatol Res 25(3):296-305, 2003

2.	Kamada Y, Tamura S, Kiso S, Matsumoto H, Saji Y, Yoshida Y, Fukui K, Maeda N, Nishizawa H, Nagaretani H, Okamoto Y, Kihara S, Miyagawa J, Shinomura Y, Funahashi T, Matsuzawa Y . Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 125(6), 1796-1807, 2003

2002

1.	Terui Y, Saito T, Watanabe H, Togashi H, Kawata S, Kamada Y, Sakuta S. Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C. Hepatology 36(4 Pt 1):1022, 2002

2001

1.	Kamada Y, Nagaretani H, Tamura S, Ohama T, Maruyama T, Hiraoka H,Yamashita S, Yamada A, Kiso S, Inui Y, Ito N, Kayanoki Y, Kawata S, MatsuzawaY. Vascular endothelial dysfunction resulting from L-arginine deficiency in a patient with lysinuric protein intolerance. J Clin Invest 108(5):717-24, 2001

1998

1.	Kamada Y, Nakajima H, Saitoh Y, Yamamoto K, Kawarada Y, Arita N, Miyagawa J, Namba M, Hanafusa T, Sugiyama T, Hayakawa T, Matsuzawa Y. A case with prolactinoma treated with pergolide and its histology. Endorc J 45(4):605-6, 1998

Phone No.

Opening Hours

Address

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

2001

1998

ご挨拶

研究紹介

研究室メンバー

研究業績

臨床研究

研究室写真

リンク

Phone No.

Opening Hours

Address

研究業績

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

2001

1998

お問い合わせ contact

ご挨拶

研究紹介

研究室メンバー

研究業績

臨床研究

研究室写真

リンク